Achieving clinical success with BET inhibitors as anti-cancer agents.
Shorstova T, Foulkes WD, Witcher M. · 2021
Read Achieving clinical success with BET inhibitors as anti-cancer agents. by Shorstova T, Foulkes WD, Witcher M. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8076232.txt.
Description
Shorstova and co-authors chart a route to clinical success for BET inhibitors in cancer. BET proteins switch on the gene networks that drive many tumors. They dock onto chromatin through two bromodomains apiece. Blocking those docks can shut the networks down. A decade of work has produced potent blockers of one or both domains.
The review lays out BET biology first. It then tracks how inhibitor design has advanced across generations. Candidate biomarkers that predict response get close attention. Resistance routes are mapped as carefully as the successes. Combination therapy forms the core strategy on offer. Pairing BET blockers with other drugs may deepen and prolong control. The authors frame three needs as the roadmap ahead. Know the mechanism, find the markers, and build the synergies.
Catalog record
| CREATOR | Shorstova T, Foulkes WD, Witcher M. |
|---|---|
| YEAR | 2021 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 87 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |